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Open access undHepatitis C-associated B-cell non-Hodgkin lymphomas:
The emerging role of miRNA-26bTo the Editor:
We read with interest the review by Peveling-Oberhag et al. [1]
that provides a very exhaustive picture of the knowledge about
HCV-related B-cell non-Hodgkin lymphomas (NHL), from its con-
nection with the mixed cryoglobulinemia (MC) condition and
epidemiology to pathomechanisms, passing through therapeutic
options.
In spite of the multiple pathogenetic hypotheses proposed for
HCV-related NHL [2], since the link between malignancy and
infection was shown [3–5], the authors clearly explained the
research advances, summarizing them in three different theories:
the sustained B cell stimulation, the direct oncogenic potential of
viral proteins, and the genetic virus-induced damage by a so
called ‘‘hit and run’’ action. Interestingly, the authors include
microRNA dysregulation in the dissertation about the ﬁrst theory,
suggesting a key role of miR-26b downregulation in undermining
tumor suppression [6]. We could recently conﬁrm these data on
NHLs and also, consistently increase the potential importance
of miR-26b levels in determining HCV-related lymphoprolifera-
tion [7]. In fact, our results showed miR-26b downregulation
not only in NHL, but also in MC patients, suggesting its involve-
ment also in this condition, considered to be a prelymphomatous
disorder. More interestingly, in patients who, after antiviral ther-
apy, experienced viral eradication, the MC syndrome disappeared
and miR-26b expression was restored to normal levels. From a
translational point of view, we could show the usefulness of
miR-26b detection in PBMCs, obtainable through non-invasive
blood sampling; this was especially interesting in consideration
of the difﬁculties in detecting miR-26b modiﬁcations in serum
samples of the same MC or NHL patients (personal, unpublished
data), making the PBMC test the easiest way to evaluate this
potential marker through a simple blood drawn. The following,
so far unexplored, step will therefore be the identiﬁcation ofJournal of Hepatology 2013
er CC BY-NC-ND license.miR-26b target genes; Peveling and colleagues already suggested
the NEK6 gene coding for a kinase involved in the initiation of
mitosis [6]. In addition, we proposed the lymphoid enhancer fac-
tor 1 (LEF-1) gene [7]. LEF-1 is a nuclear transcription factor tran-
siently expressed in the pro-B and not detectable in mature B
cells, but recently indicated as a speciﬁc target of miR-26b [8];
previous studies showed elevated levels of LEF-1 in human can-
cers, in chronic lymphatic leukemia [9] and in a wide cohort of
diffuse large B cells lymphomas [10], making this a potential tar-
get of special interest in the pathogenetic research ﬁeld.
In conclusion, our results on HCV positive MC strengthen
previous data on the importance of miR-26b modulation in
HCV-related NHL, opening new perspectives for further studies
on target genes and also aimed to a better deﬁnition of this
microRNA as disease biomarker.
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To the Editor:
Universal neonatal hepatitis B (HB) vaccination programme is
effective in the control of hepatitis B virus (HBV) infection in
countries with different endemicity [1,2]. However, the long-
term protective effect of neonatal hepatitis B vaccination into
adulthood, especially in endemic areas and to subjects with high
risk of infection, remains uncertain [3]. Universal neonatal HB
vaccination programme has been introduced in Hong Kong, a
region of moderate to high endemicity of hepatitis B, since
1988. To study the long-term effect of neonatal HB vaccination
in those with high risk of HBV infection in Hong Kong, we evalu-
ated the serial changes of HBV serological markers over a 30-year
period in a cohort born to hepatitis B carrier mothers and who
received neonatal hepatitis B vaccination.
In 1983, 1112 neonates, born to hepatitis B carrier mothers in
a public hospital in Hong Kong, were recruited for a study to eval-
uate the response of passive–active hepatitis B vaccination with
hepatitis B immunoglobulin and three-dose regimen of hepatitis
B vaccines of three different schedules: conventional (0, 1, and
6 months), delayed (2, 3, and 8 months), and accelerated (0, 1,
and 2 months) [4]. HBV serological markers, including HBsAg,
antibody to surface antigen (anti-HBs) and antibody to core-anti-
gen (anti-HBc), were determined upon completion of vaccination
and at subsequent intervals up to 30 years of follow-up. Anti-HBs
positivity was deﬁned as anti-HBs level higher or equal than
10 IU/L. Anti-HBc seroconversion was deﬁned as anti-HBc posi-
tivity for two consecutive readings measured at or after the
2nd year. Upon completion of the three-dose vaccination, 1006
(92.6%) out of 1086 subjects developed anti-HBs positivity.
Thirty-nine subjects failed the vaccination and developed chronic
HBV infection, giving the HBsAg positivity rate of 3.5%. Thirty-ﬁve
(89.7%) of them were born to mothers who were also hepatitis B
e-antigen (HBeAg) positive. All of these 39 subjects were tested
HBsAg positive before the age of two, with no new infection
found at subsequent follow-up time points of years 3, 5, 7, 10,
13, 16, 21, 25, and 30 post-vaccination (Table 1). At the 30th year
of follow-up, the anti-HBs positivity rate fell to 37.4%. There were
no differences in the development of HBsAg and anti-HBs
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positivity between subjects receiving three different vaccination
schedules (p >0.05). Ninety-seven subjects developed anti-HBc
seroconversion over the 30-year period, giving a rate of 9%
(39 subjects tested for HBsAg positive were excluded), with no
statistically signiﬁcant difference in anti-HBs positive and nega-
tive subjects (9.3% vs. 5%, p >0.05).
We described the ﬁrst study showing long-term protective
effect of neonatal HB vaccination into a cohort up to 30 years of
follow-up. While most studies reported in the literature mea-
sured immune-protection by detectable levels of antibodies to
HBV [5,6], this study provided direct evidence of effective protec-
tion in subjects with high risk of infection, both via perinatal
route or close interpersonal contact with their infected mothers
and possibly other infected household members at childhood.
Among 97 subjects who developed anti-HBc seroconversion, a
majority (43%) of these seroconversions occurred at or before
year two. On the other hand, with such a long follow-up period
up to 30 years, this study also demonstrated the protective effect
of vaccine into adulthood, when the subjects might be exposed to
horizontal transmission of HBV, notably from sexual contact.
Despite the dropping rate of anti-HBs and new occurrence of
anti-HBc seroconversion over the years, there was no new devel-
opment of HBsAg positivity after the ﬁrst two years in the entire
follow-up period.
Our ﬁndings were in line with other studies which suggested
long-term protection of HB vaccine albeit with shorter follow-up
durations. Persistence of serum protective antibody level was
shown in older children or adolescents who received vaccination
at infancy [6–8]. Moreover, anamnestic response was demon-
strated in those who had lost protective antibody level, years after
vaccination [9]. A recent study further suggested that, apart from a
protective serum antibody level, cellular immune response might
also play a role for protection against HBV after vaccination [10].
There were two limitations in this study. First, subjects who
were not followed-up might have affected the overall representa-
tiveness of the data. At the 30th year of follow-up, 246 (22.1%)
subjects returned for serological tests. 372 (33.5%) subjects
defaulted follow-up, and 492 (44.2%) subjects were lost to fol-
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